ICCM Share Price Performance
US$0.67
-0.45 (-39.74%)
78.4% undervalued intrinsic discount
US$3.13
Fair Value
Price US$0.67
AnalystConsensusTarget US$3.13
Fair ValueUS$3.13
Share Pricen/a
IceCure Medical Ltd Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
ICCM Community Narratives
AN
Fair Value US$3.13 78.4% undervalued intrinsic discount
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
Catalysts About IceCure Medical IceCure Medical develops and commercializes minimally invasive cryoablation systems for the treatment of breast and other tumors. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$3.13
78.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
168.76% p.a.
Profit Margin
0.074%
Future PE
81.65x
Price in 2028
US$0.03
Trending Discussion
Recently Updated Narratives
AN
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
Fair Value: US$3.13 78.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
IceCure Medical Ltd Key Details
About ICCM
- Founded
- 2006
- Employees
- 65
- CEO
- WebsiteView website
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
